The purpose of this study is to see if it is safe to use BufferGel in the vaginas of women
who do not have HIV and who have a low risk of getting HIV.
Many new cases of HIV are the result of heterosexual activity. Condom use is currently the
only effective way of preventing the spread of HIV and other sexually transmitted diseases
(STDs). However, women, who have a greater risk of getting HIV, are often unable to convince
their partner to use a condom. Therefore, it is important to develop methods that prevent the
spread of HIV and that are controlled by the woman, such as medicines used in the vagina.
BufferGel is known to kill the organisms that cause STDs, including HIV. BufferGel may do
this without causing genital irritation and sores as other medicines do. More studies are
needed to see if this is true.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)